Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
70results about How to "Reducing and preventing symptom" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease
InactiveUS20060167498A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesSurgical needlesSplanchnic nervesDisease
The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.
Owner:DILORENZO BIOMEDICAL
AAV vectors and methods
InactiveUS20050287122A1Easy to adaptSuitable for mass productionBiocidePeptide/protein ingredientsCapsidAdeno-associated virus
Owner:NATIONWIDE CHILDRENS HOSPITAL +1
AAV2 vectors and methods
InactiveUS6962815B2Easy to adaptSuitable for mass productionBiocideGenetic material ingredientsViral vectorCapsid
Owner:NATIONWIDE CHILDRENS HOSPITAL
Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions
InactiveUS20090118780A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesHead electrodesAfferent NeuronsAutonomic Denervation
The present invention teaches a method and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, metabolic disease, and other conditions. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism. The apparatus and methods include a conformal neuromodulator array which facilitates minimally invasive placement of neuromodulators in communication with target tissues.
Owner:DILORENZO DANIEL JOHN
Sustained release intraocular implants and methods for preventing retinal dysfunction
InactiveUS20050244506A1Few and no negative side effectFacilitate obtaining successful treatment resultsPowder deliveryBiocideMicrosphereRetinal dysfunction
Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and / or to lower intraocular pressure.
Owner:ALLERGAN INC
Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity
InactiveUS20090187230A1Reduce or prevent conditionReducing and preventing symptomSensorsDigestive electrodesAfferent NeuronsDisease
The present invention teaches methods and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism.
Owner:DILORENZO DANIEL J
Anti-aging composition, kit and method of use
InactiveUS20070237735A1Reducing and preventing age-related skin symptomReducing and preventing symptomBiocideCosmetic preparationsMADECASSIC ACIDAntioxidant
An anti-aging composition comprising: (i) at least one biomimetic oligopeptide having a sequence of 20 amino acids or less; (ii) at least one lipoaminoacid; (iii) at least one pentacyclic triterpenoid selected from the group consisting of asiaticoside, madecassic acid, asiatic acid and madecassoside; (iv) at least one antioxidant; and (v) tetrahydropiperine; a kit comprising such composition and a method of use.
Owner:LABES DERMO COSMETIK
AAV vectors and methods
InactiveUS7749492B2Easy to adaptSuitable for mass productionBiocidePeptide/protein ingredientsViral vectorCapsid
Owner:NATIONWIDE CHILDRENS HOSPITAL +1
Method of preventing or treating benign gynaecological disorders
ActiveUS8071576B2Few side-effectsLow recurrence rateBiocideOrganic active ingredientsDiseaseGynecological disorders
The present invention relates to a method of preventing or treating benign estrogen sensitive gynecological disorders in a female mammal, wherein the method comprises the administration to said female mammal of a combination of progestogen and androgen in an amount that is therapeutically effective to prevent or reduce the symptoms of these disorders. The present method is particularly suitable for preventing or treating disorders selected from the group consisting of endrometriosis, adenomyosis, uterine fibroids, dysmenorrhoea, menorrhagia and metrorrhagia. Another aspect of the invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen in an amount equivalent to 3-500 μg levonorgestrel and either 5 to 250 mg dehydroepiandrosterone or 1 to 50 mg testosterone undecanoate.
Owner:PANTARHEI BIOSCI
Methods of treatment and prevention of metabolic bone diseases and disorders
ActiveUS20080280829A1Preventing and reduce symptomInhibit activity of proteinBiocidePeptide/protein ingredientsOsteopeniaAbnormal bone marrow
The present invention provides compostions and methods useful for treating and preventing metabolic bone diseases and disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing metabolic bone diseases and disorders such as, for example osteoporosis, osteopenia and osteopenia related diseases and abnormal bone marrow.
Owner:THOMAS JEFFERSON UNIV
Phytochemicals for treatment of mastalgia and endometriosis
InactiveUS6689387B1Reducing and preventing symptomPain reduction and preventionOrganic active ingredientsBiocidePhytochemicalMedicine
New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3'diindolylmethane (LTR-1), acceptable carriers and / or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia and endometriosis.
Owner:BIORESPONSE
Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
ActiveUS7655244B2Effective treatmentReducing and preventing symptomBacterial antigen ingredientsNervous disorderSynapseVascular disease
Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.
Owner:ALLERGAN INC
Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
InactiveUS20070248586A1Minimizes or removeRelieve symptomsBiocideNervous disorderAnti-inflammatoryGamma-Linolenic acid
Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and / or GLA-derived oxylipins.
Owner:DSM IP ASSETS BV
Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
ActiveUS20060171963A1Effective prophylactic treatmentReducing and preventing symptomBacterial antigen ingredientsNervous disorderSynapseNose
Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.
Owner:ALLERGAN INC
Method and apparatus for preventing dialysis graft intimal hyperplasia
ActiveUS7553326B2Reducing and preventing symptomPrevent proliferationSurgical instrument detailsCatheterAnticarcinogenIntimal proliferation
To prevent intimal hyperplasia within a dialysis graft, a flexible tube comprising the dialysis graft is coated interiorly before placement with an anticarcinogen or mitosis-inhibiting agent for preventing cell division. The graft can also be irradiated with light energy by directing light into the lumen of the tube that has been grafted in place, thereby preventing or reducing dialysis graft intimal hyperplasia and reducing inflammation. The light source can be a light emitting diode (LED) or a chemical light source, i.e., a chemiluminescent substance for producing cool light energy within the graft to prevent or reduce the symptoms of GIH. When phototherapy is used, the body is exposed to light radiation at the site of the graft in sufficient amount to prevent undesired cell proliferation within the vessels, the graft, or surrounding tissue where the invention is used without detectable damage to body tissue.
Owner:SWEET RICHARD M
Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
InactiveUS20110021465A1Improve performanceReducing and preventing symptomBiocideSenses disorderCns degenerative diseasesAstaxanthin
A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from Krill oil, in which said krill oil contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.
Owner:US NUTRACEUTICALS LLC
Composition comprising a pde4 inhibitor and a pde5 inhibitor
InactiveUS20060094723A1Preventing and reducing onsetReduce the severity of the diseaseBiocideAntipyreticPhosphodiesterase 5 inhibitorPDE4 Inhibitors
The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and / or phosphodiesterase 5 (PDE5) is detrimental.
Owner:NYCOMED GMBH
Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
ActiveUS9320759B2Reducing and preventing symptomReducing and preventing and treating age-related deterioration of visionBiocideSenses disorderAnimal useQuality of life
Owner:SOC DES PROD NESTLE SA
Compositions and methods for inhibiting expression of pro-apoptotic genes
InactiveUS20100222409A1Reducing and preventing symptomInhibit and reduce expressionOrganic active ingredientsSugar derivativesDiseaseKEAP1
The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.
Owner:QUARK FARMACUITIKALS INC
Probiotic for administration to healthy young mammals during the weaning period for improving tolerance to newly introduced food stuffs
InactiveUS20140170126A1Enhancement of transient increase in humoral immune responsePrevent stateBiocideOrganic active ingredientsWeaningTolerability
The current invention is based upon administration of a probiotic, B. Lactis NCC2818 to healthy young mammals during the critical weaning period (in infants this period is usually from about 3 months to about 12, 18 or 24 months old), so as to accelerate the young mammal's adaptation to new food. The effectiveness of the invention is evidenced herein by morphological and immunological changes observed in a piglet animal model of weaning. Thus, administration of the probiotic according to the invention had a prophylactic effect, preventing the severe discomfort and pathological states associated with the introduction to novel foods during the weaning period.
Owner:NESTEC SA
Immunogenic compositions of staphylococcus aureus antigens
ActiveUS20120107327A1Reduce severityReduce or prevent conditionAntibacterial agentsPeptide/protein ingredientsStaphyloccocus aureusCarrier protein
The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.
Owner:WYETH LLC
Immunogenic compositions of Staphylococcus aureus antigens
ActiveUS8568735B2Reduce severityReduce or prevent conditionAntibacterial agentsPeptide/protein ingredientsStaphylococcus aureusCarrier protein
The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.
Owner:WYETH LLC
Optical detection of seizure, a pre-seizure state, and cerebral edema and optical fiber detection of the same
InactiveUS20090312646A1Degree of reductionReliable detectionDiagnostics using lightSensorsCerebral edemaSignal processing
A method for using optical parameters to monitor for a physiological event and / or a state prior to the physiological event includes the steps of: illuminating neural tissue with diagnostic light of a predetermined frequency at a predetermined location; detecting magnitude of optical scattering by neural tissue of the diagnostic light as a function of time; and determining a signature signal of the optical scattering of the diagnostic light before the physiological event in the neural tissue becomes clinically manifested. An apparatus includes a source of diagnostic light of a predetermined frequency for illuminating neural tissue at a predetermined location, a detector of optical scattering and / or optical absorption by neural tissue of the diagnostic light as a function of time, and a signal processor for determining a signature signal of the optical scattering and / or optical absorption of the diagnostic light before the physiological event becomes clinically manifested.
Owner:RGT UNIV OF CALIFORNIA
Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
InactiveUS20050202101A1Reducing and preventing symptomReduces and prevents symptomHeavy metal active ingredientsBiocideNiacinInsulin resistance
Owner:INTERHEALTH NUTRACEUTICALS
Compositions and methods for reducing or protecting against delayed graft function (DGF)
InactiveUS8785408B2Reducing and preventing symptomInhibit and reduce expressionSugar derivativesGenetic material ingredientsDiseaseApoptotic gene
The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.
Owner:QUARK FARMACUITIKALS INC
Method for Decreasing Symptoms of Alcohol Consumption
InactiveUS20120277270A1Decreasing and preventing symptom and effectReducing and preventing and effectBiocideNervous disorderMetadoxinePsychiatry
Owner:ALCOBRA LTD
GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses
InactiveUS20070212355A1Relieve symptomsReducing and preventing symptomPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseNucleic acid
Owner:BAKER AUDREY E +6
Oxylipins from stearidonic acid and .gamma.-linolenic acid and methods of making and using the same
InactiveUS7893106B2Relieve symptomsReduce and preventBiocideNervous disorderStearidonic acidOxylipin
Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and / or GLA-derived oxylipins.
Owner:DSM IP ASSETS BV
Composition comprising a pde4 inhibitor and a pde5 inhibitor
InactiveUS20100234382A1Reduce perfusionIncrease gas exchangeBiocideAntipyreticDiseasePhosphodiesterase 5 inhibitor
The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and / or phosphodiesterase 5 (PDE5) is detrimental.
Owner:NYCOMED GMBH
Keratolytic composition with anti-allergic anti-inflammatory properties
InactiveUS20060241190A1Improve securityAvoid loweringBiocideCosmetic preparationsAdjuvantAmmonium compounds
A product with an enhanced medicinal and cosmetic composition with a specific utility of “Psoriasis, Eczema and like skin disorders application” is characterized by the fact that it comprises active agents and ingredients as vanilla extract, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.
Owner:MUNISEKHAR MEDASANI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com